Safety and Potential Risks of Prolonged Use of Proton Pump Inhibitors

S.M. Tkach


Article deals with the use of proton pump inhibitors in gastroenterology. We considered the impact of proton pump inhibitors on of a variety of processes in the body, such as the absorption of vitamins and minerals, osteoporosis and fractures, the risks of infection, tumors, renal pathology. Separately, the question is raised of omeprazole interaction with other drugs.


proton pump inhibitors; omeprazole; risk; interaction


Bajaj J.S., Ratliff S.M., Heuman D.M. et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis // Aliment. Pharmacol. Ther. 2012; 36: 866-874.

Bajaj J.S., Zadvornova Y., Heuman D.M. et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites //

Am. J. Gastroenterol. 2009; 104: 1130-1134.

Banerjee S., Weideman R.A., Weideman M.W. et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention //

Am. J. Cardiol. 2011; 107: 871-878.

Bavishi C., DuPont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection // Aliment. Pharmacol. Ther. 2011;

: 1269-1281.

Bezabeh S., Mackey A.C., Kluetz P. et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors // Oncologist. 2012; 17: 550-554.

Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use // Am. J. Gastroenterol. 2008; 103: 2890-2907.

Compare D., Pica L., Rocco A. et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO // Eur. J. Clin. Invest. 2011; 41: 380-386.

Dial M.S. Proton pump inhibitor use and enteric infections // Am. J. Gastroenterol. 2009; 104 (Suppl. 2): S10-S16.

Gilard M., Arnaud B., Cornily J.C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study // J. Am. Coll. Cardiol. 2008; 51: 256-260.

Giuliano C., Wilhelm S.M., Kale-Pradhan P.B. Are proton pump inhibitors associated with the development of community acquired pneumonia? A meta-analysis // Expert. Rev. Clin. Pharmacol. 2012; 5: 337-344.

Gray S.L., LaCroix A.Z., Larson J. et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s

Health Initiative // Arch. Intern. Med. 2010; 170:


Hansen K.E., Jones A.N., Lindstrom J.M. et al. Do proton pump inhibitors decrease calcium absorption? // J. Bone Miner. Res. 2010; 25: 2510-2519.

Heidelbaugh J.J., Kim A.H., Chang R. et al. Overutilization of proton pump inhibitors: what the clinician needs to know // Therap. Adv. Gastroenterol. 2012; 5: 219-232.

Hermos J.A., Young M.M., Fonda J.R. et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed // Clin. Infect. Dis. 2012; 54: 33-42.

Herzig S.J., Howell M.D., Ngo L.H. et al. Acid-suppressive medication use and the risk for hospital-acquired pneumonia // JAMA. 2009; 301: 2120-2128.

Hess M.W., Hoenderop J.G., Bindels R.J. et al. Systematic review: hypomagnesaemia induced by proton pump inhibition // Aliment. Pharmacol. Ther. 2012; 36: 405-413.

Janarthanan S., Ditah I., Adler D.G. et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis // Am. J. Gastroenterol. 2012; 107: 1001-1010.

Johnson D.A. Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents // Curr. Gastroenterol. Rep. 2010; 12: 167-174.

Johnson D.A. Concomitant use of PPIs and antiplatelet therapy // Gastroenterol. Hepatol. 2011; 7: 7-10.

Johnstone J., Nerenberg K., Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia // Aliment. Pharmacol. Ther. 2010; 31: 1165-1177.

Kazui M., Nishiya Y., Ishizuka T. et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite // Drug. Metab. Dispos. 2010; 38: 92-99.

Khalili H., Huang E.S., Jacobson B.C. et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study // BMJ. 2012; 344: e372.

Khanna S., Aronson S.L., Kammer P.P. et al. Gastric acid suppression and outcomes in Clostridium difficile infection: a population based study // Mayo Clin. Proc. 2012; 87: 636-642

Kwok C.S., Jeevanantham V., Dawn B. et al. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis // Int. J. Cardiol. 2012 Mar 29. Epub ahead of print.

Kwok C.S., Loke Y.K. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review // Drug. Saf. 2012; 35: 127-139.

Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression // Am. J. Gastroenterol. 2007; 102: 2047-2056.

Leonard A.D., Ho K.M., Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalized patients: a case-controlled study // Intern. Med. J. 2012; 42: 591-594.

Lombardo L., Foti M., Ruggia O. et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy // Clin. Gastroenterol. Hepatol. 2010; 8: 504-508.

MacKay J.D., Bladon P.T. Hypomagnesemia due to proton pump inhibitor therapy: a clinical case series // QJM. 2010; 103: 387-395.

McColl K.E. Effect of proton pump inhibitors on vitamins and iron // Am. J. Gastroenterol. 2009; 104 (Suppl. 2): S5-S9.

Ngamruengphong S., Leontiadis G.I., Radhi S. et al. Proton pump inhibitors and risk of fracture: a systematic review and metaanalysis of observational studies //

Am. J. Gastroenterol. 2011; 106: 1209-1218.

Ratuapli S.K., Ellington T.G., O’Neill M.T. et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth // Am. J. Gastroenterol. 2012; 107:


Ray W.A., Murray K.T., Griffin M.R. et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study // Ann. Intern. Med. 2010; 152: 337-345.

Sarzynski E., Puttarajappa C., Xie Y. et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study // Dig. Dis. Sci. 2011; 56: 2243-2253.

Sierra F., Suarez M., Rey M. et al. Systematic review: proton pump inhibitor-associated acute interstitial nephritis // Aliment. Pharmacol. Ther. 2007; 26: 545-553.

Suzuki K., Doki K., Homma M. et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high dose methotrexate therapy // Br. J. Clin. Pharmacol. 2009; 67: 44-49.

Targownik L.E., Lix L.M., Leung S. et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss // Gastroenterology. 2010; 138: 896-904.

Targownik L.E., Leslie W.D., Davison K.S. et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos) // Am. J. Gastroenterol. 2012; 107: 1361-1369.

Trikudanathan G., Israel J., Cappa J. et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients — a systematic review and meta-analysis // Int. J. Clin. Pract. 2011; 65:


Van Boxel O.S., van Oijen M.G., Hagenaars M.P. et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study // Am. J. Gastroenterol. 2010; 105: 2430-2436; quiz, 2437.

Wright M.J., Sullivan R.R., Gaffney-Stomberg E. et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial // J. Bone Miner. Res. 2010; 25: 2205-2211.

Yang Y.X., Metz D.C. Safety of proton pump inhibitor exposure // Gastroenterology. 2010; 139: 1115-1127.

DOI: (51).2014.81926


  • There are currently no refbacks.

Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2017


 Яндекс.МетрикаSeo анализ сайта Рейтинг